HLB Co., Ltd. HLB Co., Ltd.

HLB Co., Ltd.

028300

株式のランク #4132
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
株価
$29.53
時価総額
$3.93B
変化(1日)
-0.12%
変化(1年)
1.82%
国
KR
取引 HLB Co., Ltd. (028300)

カテゴリー

Healthcare
HLB Co., Ltd.(028300)の営業利益率
October 2026 時点の営業利益率 TTM: -95.63%
HLB Co., Ltd. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -95.63% です。2023 年末時点では -291.43% でした。
HLB Co., Ltd. の営業利益率の履歴(2012 から 2026)
各年末の営業利益率
年 営業利益率 変化
2026 (TTM) -95.63% -45.03%
2024 -173.97% -40.30%
2023 -291.43% 601.40%
2022 -41.55% -70.94%
2021 -142.98% -12.03%
2020 -162.54% 29.91%
2019 -125.12% 54.28%
2018 -81.10% -26.51%
2017 -110.36% 42.71%
2016 -77.33% 206.50%
2015 -25.23% -1,575.44%
2014 1.71% -107.27%
2013 -23.51% 222.50%
2012 -7.29% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差 国
38.59% -100.40%
US
-149.01% -98.44%
US
25.57% -100.27%
AU
0.00% -
CH
28.81% -100.30%
NL
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。